Literature DB >> 24982550

Effect of oral administration of unfractionated heparin (UFH) on coagulation parameters in plasma and levels of urine and fecal heparin in dogs.

Malathi Erickson1, Linda M Hiebert1, Anthony P Carr1, Jocelyn D Stickney1.   

Abstract

The effects of heparin administration, by the oral route, were evaluated in dogs. In single and multiple dose studies (single 7.5 mg/kg, multiple 3 × 7.5 mg/kg per 48 h), plasma, urine, and fecal samples were collected at various times up to 120 h after oral administration of unfractionated heparin. Changes in plasma and urine anti-Xa activity, plasma and urine anti-IIa activity, plasma activated partial thromboplastin time (APTT) and antithrombin (ATIII), and chemical heparin in urine and feces were examined with time. There was support for heparin absorption, with significant differences in APTT, heparin in plasma as determined by anti-Xa activity (Heptest) in the single dose study and plasma anti-Xa activity, anti-IIa activity and ATIII; and chemical heparin in urine in the multiple dose study. No clinical evidence of bleeding was detected in any dog during the studies. Oral heparin therapy may be applicable for thromboembolic disease in animals. Further studies are warranted to determine the effects of oral heparin at the endothelial level in the dog.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24982550      PMCID: PMC4068410     

Source DB:  PubMed          Journal:  Can J Vet Res        ISSN: 0830-9000            Impact factor:   1.310


  33 in total

1.  The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin.

Authors:  R Mischke; S Grebe
Journal:  Res Vet Sci       Date:  2000-12       Impact factor: 2.534

2.  Mechanism of action and pharmacology of unfractionated heparin.

Authors:  J Hirsh; S S Anand; J L Halperin; V Fuster
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-07       Impact factor: 8.311

Review 3.  Recent advances in search of oral heparin therapeutics.

Authors:  Rishi Paliwal; Shivani R Paliwal; Govind P Agrawal; Suresh P Vyas
Journal:  Med Res Rev       Date:  2011-02-01       Impact factor: 12.944

4.  Tissue distribution and antithrombotic activity of unlabeled or 14C-labeled porcine intestinal mucosal heparin following administration to rats by the oral route.

Authors:  L M Hiebert; S M Wice; T Ping; R E Hileman; I Capila; R J Linhardt
Journal:  Can J Physiol Pharmacol       Date:  2000-04       Impact factor: 2.273

5.  Evidence of hypercoagulability in dogs with parvoviral enteritis.

Authors:  C M Otto; T M Rieser; M B Brooks; M W Russell
Journal:  J Am Vet Med Assoc       Date:  2000-11-15       Impact factor: 1.936

Review 6.  Development of oral heparin therapy for prophylaxis and treatment of deep venous thrombosis.

Authors:  S R Money; J W York
Journal:  Cardiovasc Surg       Date:  2001-06

Review 7.  Oral heparins.

Authors:  Linda M Hiebert
Journal:  Clin Lab       Date:  2002       Impact factor: 1.138

8.  Orally administered heparins prevent arterial thrombosis in a rat model.

Authors:  Cory Pinel; Sandra M Wice; Linda M Hiebert
Journal:  Thromb Haemost       Date:  2004-05       Impact factor: 5.249

9.  Prognostic factors for mortality and thromboembolism in canine immune-mediated hemolytic anemia: a retrospective study of 72 dogs.

Authors:  Anthony P Carr; David L Panciera; Linda Kidd
Journal:  J Vet Intern Med       Date:  2002 Sep-Oct       Impact factor: 3.333

10.  Delivery of therapeutic levels of heparin and low-molecular-weight heparin through a pulmonary route.

Authors:  Yiwei Qi; Ganlin Zhao; Dongfang Liu; Zachary Shriver; Mallik Sundaram; Shiladitya Sengupta; Ganesh Venkataraman; Robert Langer; Ram Sasisekharan
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-29       Impact factor: 11.205

View more
  1 in total

Review 1.  Comparative pathophysiology and management of protein-losing enteropathy.

Authors:  Melanie D Craven; Robert J Washabau
Journal:  J Vet Intern Med       Date:  2019-02-14       Impact factor: 3.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.